Skip to main content

People in the News: Paul Bianchi, Peter Rigby, Jorge Reis-Filho, Martin Bobrow, Chris Holmes, Martin Verhoef, Peter Honkanen

Premium

Illumina has named Paul Bianchi as its senior vice president of human resources. In his new role, Bianchi will oversee Illumina's global HR strategy and will manage the San Diego firm's office in Hayward, Calif.

Bianchi joins Illumina from Risk Management Solutions, where he was senior vice president of human resources. He has 20 years' experience at various companies.

Bianchi holds a master degree in management from the University of Kent in Canterbury, UK, and a BSc in managerial economics from the University of California, Davis.


Oxford Gene Technology has formed a scientific advisory board that will include Peter Rigby, who will serve as the board's chair, Jorge Reis-Filho, Martin Bobrow, and Chris Holmes.

Rigby is emeritus professor of developmental biology at the Institute of Cancer Research and deputy chairman of the board of governors at the Wellcome Trust. Reis-Filho is a professor of molecular pathology at ICR, and soon will join the Memorial Sloan-Kettering Cancer Center. Bobrow formerly was head of medical genetics at Guy's Hospital and he was deputy chairman of the Wellcome Trust and of the Nuffield Council on Bioethics. Holmes is a professor of biostatistics at the University of Oxford, head of statistical genetics at the Wellcome Trust Center for Human Genetics, and an elected member of council of the Royal Statistical Society.


Aushon BioSystems has appointed Martin Verhoef to be company CEO and to serve on its board of directors. Verhoef takes over the position from company founder Peter Honkanen, who will assume the post of chief operating officer and will continue as a board director.

Verhoef has spent 25 years in the life science research tools and molecular diagnostics business. He formerly was CEO at MiraDx and PrimeraDx, he led Ciphergen's Biosystems Division, and he held senior management jobs at Agilent in Germany and in the US.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.